• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Active ingredient in eye pain treatment passes toxicology tests


AlphaRx Inc. reported positive toxicology data for ALRX IM, an indomethacin ester and the active ingredient in Binoxan. Binoxan is a topical, non-acidic, non-steroidal anti-inflammatory pro-drug in a colloidal formulation, intended to treat ocular inflammation, eye pain, and photophobia.

With superior anti-inflammatory, analgesic, and antipyretic properties, indomethacin is normally administered in capsular form for the treatment of systemic inflammatory diseases.

The sodium salt of indomethacin can be injected intravenously or used topically for the treatment of inflammatory conditions of the eye. Indomethacin esters have comparable biologic activity to standard indomethacin formulations in animal studies, but are substantially less toxic and less irritating than the existing non-steroidal therapy.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.